Randomized controlled trial comparing clinical outcomes of Instant MSC Product accompanying Autologous Chondron Transplantation (IMPACT) for focal articular cartilage lesions of the knee to conservative treatment

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514612-27-01

Enrollment

Registered

2024-11-27

Start date

2024-12-01

Completion date

2025-08-21

Last updated

2024-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Symptomatic articular cartilage lesion of the knee (femoral condyles or trochlea)

Brief summary

The primary study parameter will be the clinical improvement and quality of life after 3, 6 and 9 months as measured with, subscales of, the KOOS and the EQ5D, respectively

Detailed description

The secondary objective of this study is to examine parameters of structural repair 6 and 18 months after treatment. This will be assessed using MRI-scans.

Interventions

DRUGInstant MSC Product accompanying Autologous Chondron Transplantation (IMPACT)

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
The primary study parameter will be the clinical improvement and quality of life after 3, 6 and 9 months as measured with, subscales of, the KOOS and the EQ5D, respectively	—

Secondary

Measure	Time frame
The secondary objective of this study is to examine parameters of structural repair 6 and 18 months after treatment. This will be assessed using MRI-scans.	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026